Israeli researchers at Tel Aviv University successfully bioengineered human spinal cord stem cells in the laboratory, demonstrating unprecedented success in animal models. The technology, developed by Prof. Tal Dvir’s team and commercialized by Matricelf, aims to restore neurological function following traumatic spinal injuries. The upcoming first-in-human transplant trial could enable paralyzed patients to regain mobility within a year, potentially transforming treatment options for spinal cord injury with regenerative medicine approaches.